IMNM
Immunome Inc.
$23.61
+2.12 (+9.87%)
At close · Jul 2
Market Cap
$2.67B
Shares
113,250,394
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
76
Net buyers
0
Net shares bought
0.00%
Net buy value
+$103,940
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2026-07-02 | Barchas Isaac |
Insider | Sell | 24,335 |
| 2026-07-02 | Barchas Isaac |
Insider | Sell | 75,665 |
| 2026-06-30 | Barchas Isaac |
Insider | Sell | 101,050 |
| 2026-06-25 | Lechleider Robert |
Chief Medical Officer | Sell | 40,580 |
| 2026-06-25 | Lechleider Robert |
Chief Medical Officer | Convert | 55,000 |
| 2026-06-25 | Lechleider Robert |
Chief Medical Officer | Sell | 14,420 |
| 2026-06-25 | Lechleider Robert |
Chief Medical Officer | Convert | 55,000 |
| 2026-06-15 | Rosett Max |
Chief Financial Officer | Sell | 60,000 |
| 2026-06-15 | Rosett Max |
Chief Financial Officer | Convert | 60,000 |
| 2026-06-15 | Rosett Max |
Chief Financial Officer | Convert | 60,000 |
| 2026-06-10 | Boylan James P |
Director | Award | 9,897 |
| 2026-06-10 | SCHAFER CAROL |
Director | Award | 9,897 |
| 2026-06-10 | Barchas Isaac |
Insider | Award | 9,897 |
| 2026-06-10 | BIENAIME JEAN JACQUES |
Director | Award | 9,897 |
| 2026-06-10 | SWAIN SANDRA M |
Director | Award | 9,897 |
| 2026-06-10 | WAGENHEIM PHILIP |
Director, 10% Owner | Award | 9,897 |
| 2026-06-05 | BIENAIME JEAN JACQUES |
Director | Buy | 6,000 |
| 2026-06-05 | BIENAIME JEAN JACQUES |
Director | Buy | 3,500 |
| 2026-06-05 | BIENAIME JEAN JACQUES |
Director | Sell | 500 |
| 2026-06-05 | BIENAIME JEAN JACQUES |
Director | Buy | 1,000 |
| 2026-06-05 | BIENAIME JEAN JACQUES |
Director | Sell | 10,000 |
| 2026-05-15 | BIENAIME JEAN JACQUES |
Director | Buy | 5,000 |
| 2026-04-02 | Rosett Max |
Chief Financial Officer | Convert | 39,713 |
| 2026-04-02 | Rosett Max |
Chief Financial Officer | Convert | 39,713 |
| 2026-04-02 | Rosett Max |
Chief Financial Officer | Sell | 1,344 |
| 2026-04-02 | Rosett Max |
Chief Financial Officer | Convert | 31,848 |
| 2026-04-02 | Rosett Max |
Chief Financial Officer | Sell | 63,656 |
| 2026-04-02 | Higgins Jack |
Chief Scientific Officer | Sell | 9,438 |
| 2026-04-02 | Rosett Max |
Chief Financial Officer | Convert | 31,848 |
| 2026-03-30 | Higgins Jack |
Chief Scientific Officer | Gift | 6,291 |
| 2026-03-27 | SIEGALL CLAY B |
Director | Buy | 25,450 |
| 2026-03-23 | WAGENHEIM PHILIP |
Director, 10% Owner | Sell | 28,200 |
| 2026-03-20 | WAGENHEIM PHILIP |
Director, 10% Owner | Sell | 36,800 |
| 2026-03-11 | BIENAIME JEAN JACQUES |
Director | Buy | 1,000 |
| 2026-03-10 | BIENAIME JEAN JACQUES |
Director | Buy | 1,000 |
| 2025-12-30 | SIEGALL CLAY B |
Director | Buy | 4,729 |
| 2025-12-22 | Barchas Isaac |
Insider | Sell | 11,251 |
| 2025-12-22 | Barchas Isaac |
Insider | Sell | 371,949 |
| 2025-12-19 | SIEGALL CLAY B |
Director | Buy | 7,278 |
| 2025-12-19 | Higgins Jack |
Chief Scientific Officer | Gift | 1,000 |
| 2025-12-19 | Higgins Jack |
Chief Scientific Officer | Gift | 1,000 |
| 2025-12-19 | SIEGALL CLAY B |
Director | Gift | 200,000 |
| 2025-12-19 | Tsai Philip |
Chief Technical Officer | Buy | 10,000 |
| 2025-12-19 | Higgins Jack |
Chief Scientific Officer | Gift | 1,000 |
| 2025-12-19 | Higgins Jack |
Chief Scientific Officer | Gift | 1,000 |
| 2025-12-19 | Higgins Jack |
Chief Scientific Officer | Gift | 1,000 |
| 2025-12-19 | Higgins Jack |
Chief Scientific Officer | Gift | 1,000 |
| 2025-12-18 | SIEGALL CLAY B |
Director | Buy | 46,511 |
| 2025-09-10 | Higgins Jack |
Chief Scientific Officer | Convert | 22,000 |
| 2025-09-10 | Higgins Jack |
Chief Scientific Officer | Convert | 22,000 |
Showing 1–50 of 215 transactions